Iradimed Corp. (IRMD) Tops Q1 EPS by 2c; Offers FY23 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil prices steady as investors weigh US-Iran war escalation
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
IRADIMED CORPORATION Announces First Quarter 2023 Financial Results
May 4, 2023 8:30 AM EDTReports record revenue of $15.5 million for the first-quarter quarter of 2023 GAAP diluted EPS of $0.27 and non-GAAP diluted EPS of $0.30 Operating income was $4.0 million and increased by 30% Announces second quarter 2023 financial guidance and increases full-year 2023 financial guidance
WINTER SPRINGS, Fla., May 04, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the Company) (NASDAQ: IRMD), announced today its financial results for the three months ended March 31, 2023. The Company is a leader in the development of innovative magnetic resonance imaging (MRI) medical devices and the... More
